Option Care Health, Inc. OPCH
We take great care to ensure that the data presented and summarized in this overview for Option Care Health, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding OPCH
View all-
Black Rock Inc. New York, NY21MShares$736 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA19.3MShares$677 Million0.01% of portfolio
-
Westfield Capital Management CO LP Boston, MA7.27MShares$255 Million0.78% of portfolio
-
State Street Corp Boston, MA6.56MShares$230 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA4.17MShares$146 Million0.01% of portfolio
-
Dimensional Fund Advisors LP Austin, TX3.99MShares$140 Million0.02% of portfolio
-
Morgan Stanley New York, NY3.74MShares$131 Million0.01% of portfolio
-
Fuller & Thaler Asset Management, Inc. San Mateo, CA3.22MShares$113 Million0.29% of portfolio
-
Northern Trust Corp Chicago, IL2.63MShares$92 Million0.01% of portfolio
-
Ubs Asset Management Americas Inc Chicago, IL2.61MShares$91.4 Million0.01% of portfolio
Latest Institutional Activity in OPCH
Top Purchases
Top Sells
About OPCH
Option Care Health, Inc. offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including Crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders. It also offers treatments to manage the progression of neurological disorders, such as amyotrophic lateral sclerosis and duchenne muscular dystrophy; infusion therapies for bleeding disorders; therapies that women need to survive and thrive through high-risk pregnancies; and other infusion therapies to treat various conditions, including pain management, chemotherapy, and respiratory medications, as well as nursing services. Option Care Health, Inc. is headquartered in Bannockburn, Illinois.
Insider Transactions at OPCH
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 28
2025
|
Michael Bavaro Chief Human Resources Officer |
SELL
Open market or private sale
|
Direct |
30,996
-40.8%
|
$1,022,868
$33.26 P/Share
|
|
Feb 28
2025
|
Michael Bavaro Chief Human Resources Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
14,739
+4.74%
|
$353,736
$24.39 P/Share
|
|
Feb 24
2025
|
Femi Adewunmi Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,287
+33.79%
|
-
|
|
Feb 24
2025
|
John Charles Rademacher Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
74,814
+9.05%
|
-
|
|
Feb 24
2025
|
Nicole Maggio Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,892
+23.38%
|
-
|
|
Feb 24
2025
|
Luke Whitworth Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
31,173
+15.32%
|
-
|
|
Feb 24
2025
|
Collin Smyser GC & Corporate Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
14,964
+16.01%
|
-
|
|
Feb 24
2025
|
Michael H. Shapiro Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
31,173
+9.09%
|
-
|
|
Feb 24
2025
|
Christopher L. Grashoff Chief Growth Officer |
BUY
Grant, award, or other acquisition
|
Direct |
13,404
+27.06%
|
-
|
|
Feb 24
2025
|
Michael Bavaro Chief Human Resources Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,599
+14.76%
|
-
|
|
Feb 23
2025
|
Christopher L. Grashoff Chief Growth Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
267
-1.16%
|
$8,544
$32.0 P/Share
|
|
Feb 23
2025
|
Luke Whitworth Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
785
-0.55%
|
$25,120
$32.0 P/Share
|
|
Feb 23
2025
|
Nicole Maggio Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
339
-2.46%
|
$10,848
$32.0 P/Share
|
|
Feb 23
2025
|
Michael Bavaro Chief Human Resources Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
267
-0.52%
|
$8,544
$32.0 P/Share
|
|
Feb 23
2025
|
John Charles Rademacher Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,872
-0.86%
|
$187,904
$32.0 P/Share
|
|
Feb 23
2025
|
Michael H. Shapiro Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,881
-0.67%
|
$60,192
$32.0 P/Share
|
|
Feb 22
2025
|
Collin Smyser GC & Corporate Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
619
-0.96%
|
$19,808
$32.0 P/Share
|
|
Feb 22
2025
|
Christopher L. Grashoff Chief Growth Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
462
-1.97%
|
$14,784
$32.0 P/Share
|
|
Feb 22
2025
|
Luke Whitworth Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,438
-1.0%
|
$46,016
$32.0 P/Share
|
|
Feb 22
2025
|
Nicole Maggio Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
357
-2.53%
|
$11,424
$32.0 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 575K shares |
|---|---|
| Open market or private purchase | 43K shares |
| Exercise of conversion of derivative security | 108K shares |
| Bona fide gift | 73.8K shares |
|---|---|
| Open market or private sale | 156K shares |
| Payment of exercise price or tax liability | 200K shares |